SEC Form 4 · accession 0001140361-18-003375
CytomX Therapeutics, Inc. · CTMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Michael Kavanaugh
Officer — CSO, Head Res.&Non-Clin. Dev.
Period of report
Jan 24, 2018
Accepted (ET)
Jan 26, 2018 · 2:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501989
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $25.82 | Jan 24, 2018 | A | 75,000 | A | — | Jan 23, 2028 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F11/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2018 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.